EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Transforming the Landscape of Drug Innovation in AI Era: AlphaFold 3 and Beyond

Songlin He, Liangbin Zhou, Xiaoshuai Wang, Chenzhong Li, Cheng Jiang, Rocky S Tuan, Zhong Alan Li

Exploration · 2026-10 · 6 (5)

DOI: 10.1002/exp2.70236 ↗

At a glance

Journal article in Exploration, published online on 2026-10-11. Written by Songlin He and 6 co-authors. Institution: Department of Biomedical Engineering, Faculty of Engineering The Chinese University of Hong Kong Hong Kong SAR China. 33 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The traditional drug discovery and development (DDD) pipeline has long been characterized by inefficiency and high costs. The rapid evolution of artificial intelligence (AI), especially AI‐based toolkits for protein structure and interaction prediction, exemplified by AlphaFold 3 (AF3), promises to reshape the landscape of drug innovation. AF3 advances structural biology by predicting protein structures and their interactions with a range of biomolecules, including nucleic acids, small‐molecule ligands, and ions, potentially changing the conventional DDD paradigm, although prediction accuracy varies substantially across these categories. This perspective examines the impact of AF3 on drug target identification and validation, hit identification, lead optimization, and personalized clinical decision‐making, while addressing the technical challenges, ethical considerations, and governance implications. Solutions to overcome current limitations are proposed to advance the development of novel therapeutics.

Subjects

Author keywords

AlphaFold 3artificial intelligencedrug discovery and developmentpersonalized medicineprotein structure prediction

Authors and institutions

  • Department of Biomedical Engineering, Faculty of Engineering The Chinese University of Hong Kong Hong Kong SAR China.
  • InnoHK Center for Neuromusculoskeletal Restorative Medicine Hong Kong Science and Technology Park Hong Kong SAR China.
  • Department of Rehabilitation Medicine The Third Affiliated Hospital Southern Medical University Guangzhou Guangdong China.
  • School of Medicine The Chinese University of Hong Kong Shenzhen China.
  • Institute For Tissue Engineering and Regenerative Medicine, School of Biomedical Sciences The Chinese University of Hong Kong Hong Kong SAR China.
  • Peter Hung Pain Research Institute, Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China.

Funding

  • National Natural Science Foundation of China

Cite

APA

He, S., Zhou, L., Wang, X., Li, C., Jiang, C., Tuan, R. S., & Li, Z. A. (2026). Transforming the Landscape of Drug Innovation in AI Era: AlphaFold 3 and Beyond. Exploration, 6(5). https://doi.org/10.1002/exp2.70236

Vancouver

He S, Zhou L, Wang X, Li C, Jiang C, Tuan RS, et al. Transforming the Landscape of Drug Innovation in AI Era: AlphaFold 3 and Beyond. Exploration. 2026;6(5). doi:10.1002/exp2.70236

BibTeX
@article{He2026,
  author = {He, Songlin and Zhou, Liangbin and Wang, Xiaoshuai and Li, Chenzhong and Jiang, Cheng and Tuan, Rocky S and Li, Zhong Alan},
  title = {Transforming the Landscape of Drug Innovation in AI Era: AlphaFold 3 and Beyond},
  journal = {Exploration},
  year = {2026},
  volume = {6},
  number = {5},
  doi = {10.1002/exp2.70236}
}
Start for free →